Harvard Bioscience (NASDAQ:HBIO) Now Covered by StockNews.com

StockNews.com started coverage on shares of Harvard Bioscience (NASDAQ:HBIO) in a research note issued to investors on Sunday morning. The brokerage issued a hold rating on the medical instruments supplier’s stock.

Several other equities analysts have also recently weighed in on the company. Benchmark lowered their target price on Harvard Bioscience from $5.50 to $4.50 and set a “speculative buy” rating on the stock in a research note on Monday, March 24th. KeyCorp restated a “sector weight” rating on shares of Harvard Bioscience in a report on Wednesday, April 9th.

Harvard Bioscience Stock Performance

Shares of Harvard Bioscience stock opened at $0.39 on Friday. Harvard Bioscience has a 12 month low of $0.36 and a 12 month high of $4.08. The company has a quick ratio of 0.91, a current ratio of 2.06 and a debt-to-equity ratio of 0.52. The stock has a market cap of $17.10 million, a PE ratio of -1.18 and a beta of 1.47. The business has a fifty day simple moving average of $0.71 and a 200-day simple moving average of $1.64.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. AMH Equity Ltd lifted its holdings in shares of Harvard Bioscience by 4.7% during the 4th quarter. AMH Equity Ltd now owns 2,500,000 shares of the medical instruments supplier’s stock valued at $5,275,000 after buying an additional 111,132 shares during the last quarter. Royce & Associates LP increased its stake in shares of Harvard Bioscience by 35.4% during the 4th quarter. Royce & Associates LP now owns 1,965,114 shares of the medical instruments supplier’s stock worth $4,146,000 after purchasing an additional 513,664 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Harvard Bioscience by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 912,599 shares of the medical instruments supplier’s stock valued at $2,455,000 after purchasing an additional 19,972 shares in the last quarter. State Street Corp lifted its stake in shares of Harvard Bioscience by 1.1% in the 3rd quarter. State Street Corp now owns 717,387 shares of the medical instruments supplier’s stock valued at $1,930,000 after purchasing an additional 7,763 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Harvard Bioscience by 11.1% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 200,032 shares of the medical instruments supplier’s stock worth $422,000 after purchasing an additional 20,026 shares in the last quarter. Hedge funds and other institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.